Dr. Alberto Lleó is the director of the Memory Unit of the Neurology Department at Hospital de la Santa Creu i Sant Pau.
After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona and continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.
In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.
Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.
- Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. Lleó, A, Parnetti, L, Belbin, O et al. Clin. Chim. Acta 2019PMID:30682327
- Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Westwood, S, Baird, AL, Hye, A et al. Front Aging Neurosci 2018PMID:30618716
- Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer's disease cerebrospinal fluid. Lleó, A, Núñez-Llaves, R, Alcolea, D et al. Mol. Cell Proteomics 2019PMID:30606734
- Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Lopez-Font, I, Sogorb-Esteve, A, Javier-Torrent, M et al. Neurobiol. Dis. 2019PMID:30594809
- HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. Menéndez-González, M, Clarimón, J, Rosas-Allende, I et al. Neurobiol. Aging 2018PMID:30583877
- Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. Delaby, C, Muñoz, L, Torres, S et al. Clin. Chim. Acta 2019PMID:30579960
- LRP10 in α-synucleinopathies. Guerreiro, R, Orme, T, Neto, JL et al. Lancet Neurol 2018PMID:30507384
- Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Swarup, V, Hinz, FI, Rexach, JE et al. Nat. Med. 2019PMID:30510257
- A comprehensive screening of copy number variability in dementia with Lewy bodies. Kun-Rodrigues, C, Orme, T, Carmona, S et al. Neurobiol. Aging 2019PMID:30448004
- Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. Pegueroles, J, Jiménez, A, Vilaplana, E et al. Oncotarget 2018PMID:30410669
- Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. Giménez, S, Videla, L, Romero, S et al. J Clin Sleep Med 2018PMID:30353801
- Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Ramos de Matos, M, Ferreira, C, Herukka, SK et al. J. Alzheimers Dis. 2018PMID:30320580
- Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. Alcolea, D, Irwin, DJ, Illán-Gala, I et al. J. Neurol. Neurosurg. Psychiatry 2019PMID:30297518
- CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum. Illán-Gala, I, Alcolea, D, Montal, V et al. Neurology 2018PMID:30291183
- Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Bergeron, D, Gorno-Tempini, ML, Rabinovici, GD et al. Ann. Neurol. 2018PMID:30255971